Merrill Lynch Keeps a Sell Rating on Myriad Genetics (MYGN)

By Austin Angelo

Merrill Lynch analyst Derik De Bruin maintained a Sell rating on Myriad Genetics (NASDAQ: MYGN) today and set a price target of $34. The company’s shares opened today at $43.50.

According to TipRanks.com, Bruin is a 3-star analyst with an average return of 2.1% and a 56.3% success rate. Bruin covers the Healthcare sector, focusing on stocks such as Exact Sciences, Danaher Corp, and Waters Corp.

Myriad Genetics has an analyst consensus of Moderate Buy, with a price target consensus of $42.83.

See today’s analyst top recommended stocks >>

The company has a one-year high of $48.87 and a one-year low of $27.23. Currently, Myriad Genetics has an average volume of 728K.

Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. Last month, Richard M. Marsh, the E.V.P., General Counsel of MYGN sold 70,672 shares for a total of $3,029,968.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through two segments: Diagnostics and Other.